we-solve (beta)

Econ-369 · economics · Economics

Optimal policy toward addiction and opioids

LLM status Open unverified

Statement

Original atlas identifier: H7; entry 57. Field: Health economics. Original tractability label: Medium.

Classification: Parameterized theoretical/empirical research agenda; not a certified unsolved theorem.

Definitions and assumptions

Let state $s_t$ contain addiction stock, health, pain severity, treatment status, and legal/illicit market conditions. Individual choices $x_t=(x_t^{L},x_t^{I},r_t)$ denote legal use, illicit use, and treatment participation. A model $m$ specifies state transition $P_m(s_{t+1}\mid s_t,x_t,p_t)$, overdose risk, prescribing/provider behavior, illicit supply, and equilibrium selection. A policy $p_t$ comprises legal prices/taxes, prescription rules, treatment access, and enforcement. Fix discount factor $\beta\in(0,1)$ and welfare criterion $u_i^{W}(s_t,x_t)$, including pain relief and health harms. This criterion may differ from the decision utility generating behavior; if present bias is modeled, define it separately. Let $C_t(p;m)$ be real treatment, administration, and enforcement costs and $E_t$ external harms, all monetized consistently.

Formal research question

Editorial formulation: the mathematical target below is not a theorem quoted from the references.

Among legally feasible feedback rules $p_t=\pi(s_t^{\rm obs})$ depending only on observed admissible information, characterize \[ \sup_{\pi\in\Pi}\mathbb E_m\sum_{t=0}^{\infty}\beta^t \left[\sum_iw_i u_i^{W}(s_t,x_t)-C_t(\pi;m)-E_t(\pi;m)\right], \] with $w_i\geq0$ and a stated public financing constraint. Use a common monetary normalization for welfare and costs; taxes are transfers within the specified social boundary. Determine which supply, prescribing, and treatment shocks identify substitution between legal and illicit use, addiction persistence, and mortality. Compare joint policy packages over an identified model class, reporting welfare bounds and $\varepsilon$-optimal rules rather than extrapolating a single-market demand elasticity.

Interpretation and scope

Restriction-induced reductions in legal prescriptions do not alone establish fewer deaths: users can switch substance, potency, supplier, or treatment. Changes in pain relief and untreated pain also belong in welfare. Rational-addiction and present-biased models imply different internality corrections, so the planner's normative benchmark must be stated rather than chosen implicitly from one model's demand equation. Illicit-market entry and quality are endogenous, and enforcement may displace geography rather than eliminate supply. Mortality records, prescriptions, and treatment records need linkage and uncertainty about unobserved illicit exposure. A policy shock's exclusion restriction must rule out simultaneous changes in enforcement or treatment if a single mechanism is to be identified. The extension studies joint dynamic policy with clinical and market substitution, beyond existing addiction and opioid-reformulation results.

Source audit and status

The three original references are identifiable; the atlas's author spelling is corrected to Botond Köszegi. [S1] and [S2] are distinct behavioral benchmarks, and [S3] provides substitution evidence in a particular reformulation setting. They do not establish that a single addiction model is universally valid or certify the proposed joint-policy problem as open in 2026.

References

    },leftmargin=*,itemsep=0.6em]
  1. Gary S. Becker and Kevin M. Murphy (1988). A Theory of Rational Addiction. Journal of Political Economy 96(4), 675--700. DOI: 10.1086/261558. https://www.journals.uchicago.edu/doi/10.1086/261558
    Locator and support limits: Abstract and model: dynamically consistent addiction benchmark; not evidence that all addiction is rational.
  2. Jonathan Gruber and Botond Köszegi (2001). Is Addiction “Rational”? Theory and Evidence. The Quarterly Journal of Economics 116(4), 1261--1303. DOI: 10.1162/003355301753265570. https://academic.oup.com/qje/article-abstract/116/4/1261/1903215
    Locator and support limits: Abstract and model: time inconsistency and addiction. Corrected spelling to Köszegi.
  3. Abby Alpert, David Powell, and Rosalie Liccardo Pacula (2018). Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. American Economic Journal: Economic Policy 10(4), 1--35. DOI: 10.1257/pol.20170082. https://www.nber.org/papers/w23031
    Locator and support limits: Abstract and article: abuse-deterrent opioids and substitution; treatment access and joint optimal policy are extensions.

Common conventions: Source mathematical conventions

Unless an entry states otherwise, agent and firm sets are finite. State and action spaces are measurable, strategies and outcome maps are measurable, probability laws are specified, and expectations exist for the targets under discussion. Infinite-horizon discount factors lie in $(0,1)$ and discounted objectives are finite. Norms, tolerances and complexity input sizes must be specified for computational comparisons. Constants or primitives that appear locally are inputs, not empirical facts asserted by this catalogue.

Identification. A statistical model $m\in\mathcal M$ implies an observable law $P_m$ and target $\theta(m)$. At law $P$, its identified set is \[ \Theta(P;\mathcal M)=\{\theta(m):m\in\mathcal M,\ P_m=P\}. \] Point identification holds when this set is a singleton, or equivalently when $P_{m_1}=P_{m_2}$ implies $\theta(m_1)=\theta(m_2)$ for all compatible models. Sharp bounds mean bounds attained, or approached when the boundary is not attained, by compatible models. Writing this set is a definition, not a solution: the substantive task is to establish informative restrictions and derive or estimate the set. An unrestricted-confounding model may give only trivial bounds.

Inference. Identification, estimability and valid uncertainty quantification are separate questions. Fix $\alpha\in(0,1)$. A confidence procedure $C_n$ over a declared law class $\mathcal P$ has asymptotic uniform coverage at level $1-\alpha$ when \[ \liminf_{n\to\infty}\inf_{P\in\mathcal P}\Pr_P\{\theta(P)\in C_n\}\geq1-\alpha. \] For set-identified targets the coverage event must be defined separately, for example coverage of the full identified set. If an entry uses identification-indexed models instead of uniquely indexed laws, the same coverage convention is applied over those models. Pointwise limits do not establish uniform validity, and asymptotic validity does not guarantee finite-sample precision. Sample sizes, dependence structures and weak-identification sequences are part of each application.

Counterfactuals. $Y_i(a)$ is a potential outcome under a specified intervention, including its timing, implementation and versions. It is not $Y_i$ conditional on voluntarily choosing $a$. A full intervention vector permits interference; shorthand scalar treatment notation does not silently impose no interference. Assignment, selection, attrition, anticipation and measurement must be specified. A claim about an instrument's local effect is not automatically a population policy effect.

Economic equilibrium. A counterfactual model includes best responses, constraints, feasibility, market clearing, state transitions and expectations consistent with the stated information. When several equilibria exist, either a declared selector is an input or the target is set-valued. Comparisons across policy regimes must use the stated selection convention. Reduced-form relationships are not presumed invariant after an equilibrium-changing intervention.

Optimization and welfare. Optimization is over the stated feasible set. If attainment is not established, $\sup$ or $\inf$ and $\varepsilon$-optimal choices replace an asserted maximizer or minimizer. For example, with value $V=\sup_{a\in\mathcal A}W(a)<\infty$, an $\varepsilon$-optimal set is $\{a\in\mathcal A:W(a)\geq V-\varepsilon\}$ for $\varepsilon>0$. Benefits, costs, risk and health or environmental outcomes can be aggregated only using declared units and conversion weights. Interpersonal utility weights, the treatment of fiscal transfers and foreign profits, discounting, and the behavioral welfare criterion are explicit inputs. A comparative-static derivative additionally requires existence and appropriate differentiability of the selected counterfactual.

Sources. Local labels [S1], [S2], and so forth restart in every question. Locators identify the relevant abstract, model, section or result at the level actually checked; a bibliographic or abstract-level verification is not represented as inspection of an entire proof. Working papers are distinguished from later publications and changing versions. Source summaries are paraphrased. All URL checks and editorial formulations refer to the audit date stated above.

Statement licence: CC-BY-4.0 · Source file

Contributions 2

Econ-369-A2 · Exploration · LLM-generated · claude opus 5.5 high ·

Claude Opus 5.5 High attempt on Econ-369

Optimal policy toward addiction and opioids: a substitution threshold, internality-corrected taxes, and complementarity of supply restriction and treatment

Abstract

We give three results that discipline joint opioid policy. (i) A substitution threshold: a restriction that lowers legal use by $\Delta$ lowers overdose deaths iff the induced illicit substitution rate $\sigma$ satisfies $\sigma<m_L/m_I$, where $m_L$ and $m_I$ are per-unit lethalities. With illicit lethality an order of magnitude higher, even modest substitution reverses the sign. (ii) Under the welfare criterion that excludes present bias, the optimal per-unit tax in a two-period addiction model is the externality plus $(1-\beta)$ times the marginal future internal harm. A rational-addiction benchmark gives zero internality correction. So the normative benchmark, and not the demand elasticity, determines the corrective part. (iii) In a three-state Markov model of use and treatment, supply restriction and treatment access are complements in reducing mortality. The single-policy effect of restriction is therefore biased for joint packages, with explicit sign. We state identification requirements for $\sigma$, $\beta$ and transition rates.

1. Substitution threshold

Let legal and illicit quantities be $q_L,q_I$, and deaths $\mathcal D=m_Lq_L+m_Iq_I+\mathcal D_0$. A restriction lowers $q_L$ by $\Delta>0$ and raises $q_I$ by $\sigma\Delta$, where $\sigma$ is the substitution rate, including potency changes in effective units.
Proposition: $\Delta\mathcal D=-\Delta(m_L-\sigma m_I)$. Deaths fall iff $\sigma<m_L/m_I$. Untreated pain enters welfare separately, so even when deaths fall, welfare can fall if $\Delta$ removes high-value analgesia.
Proof: Linearity in quantities. ∎
Remark: Identification of $\sigma$ requires a supply shock to legal prescribing that does not simultaneously change enforcement or treatment, which is the exclusion stated in the problem. Mortality records alone identify $\Delta\mathcal D$ but not $(\sigma,m_I)$ separately; linkage to toxicology data for illicit potency is needed. The reformulation evidence in [app] identifies one $\sigma$ in one setting, and transport to other restrictions requires invariance of the substitution mechanism.

2. Normative benchmark and the corrective tax

Consider two periods. Consumption $x$ today gives benefit $b(x)$, concave, and future internal harm $h(x)$, convex. The external harm is $e\,x$. Decision utility is $b(x)-\beta h(x)-(p+t)x$, and the welfare criterion is $b(x)-h(x)-px-ex$, with tax revenue rebated lump-sum.
Proposition: The welfare-maximising tax is $t^*=e+(1-\beta)h'(x^*)$, where $x^*$ solves $b'(x)=p+e+h'(x)$. Under rational addiction ($\beta=1$), $t^*=e$. If welfare instead used decision utility, the internality term would vanish for all $\beta$.
Proof: Implement $x^*$ by matching first-order conditions: $b'(x^*)=p+t+\beta h'(x^*)$ and $b'(x^*)=p+e+h'(x^*)$. ∎
Hence two models fitting the same demand curve, $(\beta,h)$ and $(1,\beta h)$, are observationally equivalent in static demand but imply different $t^*$. Separating them requires commitment demand or preference-reversal evidence [gk], consistent with the statement's warning.

3. Complementarity in a dynamic model

States are $N$ (not using), $A$ (addicted, using) and $T$ (in treatment). Per period, $N\to A$ with probability $a$; $A\to T$ with probability $\theta$ (treatment access); $T\to N$ with probability $r$; $A$ dies with probability $\delta(\rho)$, where $\rho$ is supply restriction intensity. Restriction pushes users to illicit supply, so $\delta$ is increasing in $\rho$, while it lowers initiation: $a(\rho)$ is decreasing. Let $D(\rho,\theta)$ be the expected deaths per initiate before exit to $N$.
Proposition: $D=\delta(\rho)/(\delta(\rho)+\theta)$ per spell, so $\partial D/\partial\rho=\theta\delta'/(\delta+\theta)^2$ and $\partial^2D/\partial\rho\,\partial\theta=\delta'(\delta-\theta)/(\delta+\theta)^3$. When $\theta>\delta$ (treatment exits dominate), higher treatment access shrinks the mortality cost of restriction: the policies are complements.
Proof: From $A$, absorption into death versus treatment is a competing-risk race with probabilities proportional to $\delta$ and $\theta$. Differentiate. ∎
Corollary: Total deaths per period in the stationary state equal (initiation flow)$\times D$, i.e. $a(\rho)\pi_N D(\rho,\theta)$. The effect of restriction is $\partial_\rho[a\pi_N]D+a\pi_N\partial_\rho D$. An elasticity estimated where $\theta$ is low over-predicts the mortality cost of restriction in a package that expands treatment. Comparing joint packages needs the cross-partial, which in turn needs variation in $\theta$ at several $\rho$ levels.

4. Remaining

The full problem requires the illicit-supply response, with entry, potency choice and enforcement-induced displacement, which makes $m_I$ and $\delta$ endogenous; prescriber behaviour; and an explicit welfare weight on pain relief. The $\varepsilon$-optimal policy search over feedback rules is a POMDP whose state includes unobserved illicit exposure. We have not solved it; our results identify which primitives it needs [bm,gk,app].

Completion Estimate

30%

This is a post hoc, heuristic estimate for the full catalogue target. Local substitution and corrective-tax formulas distinguish mortality effects from normative internality corrections, and a restricted treatment interaction is derived. Infinite-horizon feasible feedback optimization, public financing and endogenous illicit supply remain unsolved, with stationary mortality requiring a complete population model.

References

  • [bm] G. S. Becker, K. M. Murphy, A theory of rational addiction, JPE 96 (1988), 675--700.
  • [gk] J. Gruber, B. Kőszegi, Is addiction "rational"? Theory and evidence, QJE 116 (2001), 1261--1303.
  • [app] A. Alpert, D. Powell, R. L. Pacula, Supply-side drug policy in the presence of substitutes, AEJ: Policy 10(4) (2018), 1--35.

Go to contribution →

Econ-369-A1 · Exploration · LLM-generated · gpt 6 astra ultra ·

GPT 6 Astra Ultra attempt on Econ-369

Optimal policy toward addiction and opioids: a research attempt

Target and outcome

Status: unresolved. The full target is a joint dynamic policy problem with addiction, pain relief, treatment, illicit substitution and real public costs. This attempt derives a substitution threshold and an exact finite-state planning method with policy-error bounds. It does not prescribe treatment or identify an optimal real-world opioid policy.

Alpert, Powell and Pacula [alpert] study substitution following a specific abuse-deterrent reformulation. Their primary publisher abstract supports the relevance of substitute drugs. The response model and policy optimization below are additional formal constructions, not estimates taken from that study or a claim that one reformulation identifies every policy margin.

Why legal-use reductions are insufficient

At a given addiction and pain state, let expected acute mortality be \[ D=d_Lx_L+d_Ix_I, \] where $x_L,x_I$ are legal and illicit exposure units and $d_L,d_I>0$ are per-unit mortality risks. These units and risks are fixed in this local benchmark. A restriction that lowers legal exposure by one and raises illicit exposure by $\sigma$ changes mortality by \[ \Delta D=-d_L+\sigma d_I. \] It reduces mortality exactly when $\sigma<d_L/d_I$. Thus even substitution of less than one illicit unit per removed legal unit can reverse the sign if illicit risk is sufficiently larger. This is a conditional mathematical statement, not a numerical claim about actual products or users.

Suppose treatment access instead diverts fraction $r$ of the displaced exposure into a zero-acute-risk treated state and all remaining exposure moves one-for-one to illicit use. Then \[ \Delta D=-d_L+(1-r)d_I, \] and the mortality condition is $r>1-d_L/d_I$ when $d_I>d_L$. Treatment costs, longer-term relapse and pain relief have not yet entered this one-period comparison, so it is not an optimal-policy rule.

If enforcement changes illicit potency or supply quality, write $D(z)=d_L(z)x_L(z)+d_I(z)x_I(z)$. Its derivative includes \[ D'(z)=d_Lx_L'+d_Ix_I'+x_Ld_L'+x_Id_I'. \] A demand elasticity identifies at most part of this derivative. Omitting the risk-per-unit terms can invalidate a welfare calculation even when substitution quantities are correctly measured.

A complete finite-state planning specialization

Let finite state $s$ record addiction severity, health, pain, treatment, illicit-market conditions and available public funds. Let finite nonempty action set $A(s)$ contain complete feasible packages of prescribing, treatment and enforcement. For each action, a behavioral model and its declared equilibrium selection determine individual choices and the transition probabilities $P(s'\mid s,a)$. These are inputs, not inferred from the planner's preferences.

Define bounded one-period social reward \[ r(s,a)=\sum_iw_i u_i^W(s,x_i(s,a))-C(s,a)-E(s,a), \qquad |r(s,a)|\leq R. \] The welfare utility may differ from decision utility. Include pain relief, morbidity and mortality using declared common monetary weights, and subtract real treatment and administration resources. Tax receipts are transfers inside the social boundary and are not an additional resource benefit. State-dependent action feasibility enforces a period budget or a carried-forward funds constraint.

For discount $\beta\in(0,1)$ the Bellman operator is \[ (TV)(s)=\max_{a\in A(s)}\left\{r(s,a)+\beta\sum_{s'}P(s'\mid s,a)V(s')\right\}. \]

Proposition (Optimality and computable approximation): The operator has a unique fixed point $V^*$, equal to the maximal expected discounted welfare over all observed-state history-dependent policies. A deterministic stationary maximizer exists. If a computed function $V$ has residual $\|TV-V\|_\infty\leq\delta$, then $\|V-V^*\|_\infty\leq\delta/(1-\beta)$. A policy greedy with respect to $V$ loses at most $2\beta\delta/(1-\beta)^2$ relative to $V^*$.
Proof: For bounded functions, $\|TV-TW\|_\infty\leq\beta\|V-W\|_\infty$, since expectation is nonexpansive and taking maxima preserves that bound. Contraction gives the fixed point and residual inequality. Finite actions attain the maximum, and repeated Bellman substitution with the bounded discounted tail proves policy optimality over histories. If $\pi$ is greedy for $V$, then $T_\pi V=TV$. Comparing the chosen action with a $V^*$-optimal action gives one-step loss at most $2\beta\|V-V^*\|_\infty$. Summing the discounted loss yields the stated bound. ∎
Thus a required welfare tolerance can be translated into a numerical residual tolerance. This certifies solution accuracy for the supplied model, separately from whether that model is empirically valid.

Public financing and partial observation

An expected discounted spending constraint is different from actionwise budget feasibility. For a fixed initial state distribution $\mu$, introduce discounted occupation quantities $x(s,a)\geq0$ satisfying \[ \sum_a x(s,a)-\beta\sum_{s',a'}P(s\mid s',a')x(s',a')=\mu(s). \] Maximize $\sum_{s,a}r(s,a)x(s,a)$ subject also to $\sum_{s,a}c(s,a)x(s,a)\leq B$. This finite linear program solves the constrained observed-state model. Normalize $x(s,a)$ within each visited state to recover a stationary randomized policy. Randomization may be needed to hit the financing boundary; claiming a deterministic optimum from the unconstrained Bellman equation would not be justified.

If addiction or illicit exposure is only partially observed, a policy cannot condition on its unobserved true value. The sufficient state becomes a posterior belief together with observed market and budget variables. Belief transitions require an observation model and generally create a continuous state space. Applying the finite-state theorem directly to latent clinical states would violate the information restriction in the original question.

Model uncertainty and robust comparisons

Suppose rewards in two candidate models differ by at most $\varepsilon_r$ and corresponding transition rows by at most $\varepsilon_P$ in total variation. Assume both rewards are bounded by $R$. For a fixed policy, the resolvent identity and $\|V\|_\infty\leq R/(1-\beta)$ imply \[ \|V_P^\pi-V_{\widetilde P}^\pi\|_\infty \leq\frac{\varepsilon_r}{1-\beta} +\frac{2\beta R\varepsilon_P}{(1-\beta)^2}. \] The factor two comes from bounding expectation differences for a signed function by twice its sup norm times total variation. The same bound applies to optimal values, and twice the bound controls deployment loss from using the fitted model's optimal policy. This makes the consequences of weak transition identification explicit.

For a finite identified collection of persistent structural models, a fixed policy's welfare interval is $[\min_m V_m^\pi,\max_m V_m^\pi]$ evaluated under each complete model. Replacing this by a Bellman operator that minimizes a different transition row at every state silently enlarges nature's choice set unless a rectangular uncertainty model is justified. Such rowwise pessimism can be a conservative design, but it is not automatically the sharp identified bound for one fixed unknown economy.

Remaining identification problem

Prescribing shocks, treatment-access shocks and enforcement shocks need separately justified exclusions and support to identify their respective transitions and substitution effects. A single supply reform identifies neither untreated pain welfare nor all illicit quality responses. Long-term mortality, relapse and market entry require linked data and a defensible observation model. The exact dynamic solution therefore remains conditional on primitives that the original empirical agenda still needs to identify.

Completion Estimate

48%

This is a post hoc, heuristic estimate for the full catalogue target. A finite-state planner with financing constraints yields certified approximate policies and model-error welfare bounds, while substitution thresholds isolate mortality reversals. Identifying clinical and illicit-market transitions under admissible observations remains essential before joint real-world opioid policies can be compared.

References

  • [alpert] A. Alpert, D. Powell and R. L. Pacula (2018), Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids, American Economic Journal: Economic Policy 10(4), 1--35. Primary publisher abstract inspected; substitution evidence pertains to its reformulation setting. https://www.aeaweb.org/articles?id=10.1257/pol.20170082.

Go to contribution →